Cargando…
Design, Synthesis, In Vitro and In Vivo Evaluation of Heterobivalent SiFAlin-Modified Peptidic Radioligands Targeting Both Integrin α(v)β(3) and the MC1 Receptor—Suitable for the Specific Visualization of Melanomas?
Combining two peptides addressing two different receptors to a heterobivalent peptidic ligand (HBPL) is thought to enable an improved tumor-targeting sensitivity and thus tumor visualization, compared to monovalent peptide ligands. In the case of melanoma, the Melanocortin-1 receptor (MC1R), which i...
Autores principales: | Cheng, Xia, Hübner, Ralph, von Kiedrowski, Valeska, Fricker, Gert, Schirrmacher, Ralf, Wängler, Carmen, Wängler, Björn |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8228600/ https://www.ncbi.nlm.nih.gov/pubmed/34200477 http://dx.doi.org/10.3390/ph14060547 |
Ejemplares similares
-
Current State of Radiolabeled Heterobivalent Peptidic Ligands in Tumor Imaging and Therapy
por: Judmann, Benedikt, et al.
Publicado: (2020) -
Synthesis, Radiolabeling,
and In Vitro and In Vivo Characterization
of Heterobivalent
Peptidic Agents for Bispecific EGFR and Integrin α(v)β(3) Targeting
por: Braun, Diana, et al.
Publicado: (2023) -
Design, Synthesis, In Vitro, and Initial In Vivo Evaluation of Heterobivalent Peptidic Ligands Targeting Both NPY(Y(1))- and GRP-Receptors—An Improvement for Breast Cancer Imaging?
por: Vall-Sagarra, Alicia, et al.
Publicado: (2018) -
Toward Optimized (89)Zr-Immuno-PET: Side-by-Side Comparison of [(89)Zr]Zr-DFO-, [(89)Zr]Zr-3,4,3-(LI-1,2-HOPO)- and [(89)Zr]Zr-DFO*-Cetuximab for Tumor Imaging: Which Chelator Is the Most Suitable?
por: Damerow, Helen, et al.
Publicado: (2022) -
Toward the Development
of GE11-Based Radioligands
for Imaging of Epidermal Growth Factor Receptor-Positive Tumors
por: Judmann, Benedikt, et al.
Publicado: (2022)